Yi et al. combined the STING agonists and the anti-TGF-β/PD-L1 bispecific antibody successfully enhanced innate and acquired immunity in mice, promoted antigen presentation, improved T-cells migration and chemotaxis, and upregulated the number and activity of tumor-infiltrating lymphocytes, demonstrating new perspectives for overcoming immunotherapy resistance (Yi et al., 2022). The gene discussed is STING1; the disease is neoplasm.